Introduction and HPV-Testing
============================

The preventive strategy for cervical cancer is based on identification and treatment of high-grade cervical lesions (HG-CIN) in order to prevent cancer progression. Thus, although conservative, it represents a surgically-based approach (usually by means of laser, cold-knife cone biopsy, or loop electrosurgical excision procedure \[LEEP\]), which results in an overall high-rate of success. Nevertheless, treatment failures within 2 years (in terms of residual or recurrent high-grade cervical disease) may occur in approximately 5-15% of cases, or even more \[\[1\],\[2\],\[3\],\[4\]\], thus often requiring subsequent re-excisional therapy. Moreover, CIN2 and mainly CIN3 treated patients (recognized as the true pre-cancer cervical lesion) remain at high-risk for cervical or other lower-genital tract HPV-related diseases over time. Indeed, for many years the post-treatment risk of invasive cervical cancer is still five-fold greater in such women than that in the general population \[\[5\]\]. Furthermore, it has been estimated in the UK that 16% of diagnosed cervical cancers had previously been treated for intraepithelial neoplasia \[\[6\]\], confirming the need for a careful and close follow-up of such patients, at least for 10 years after therapy.

For these reasons, high-grade CIN-treated patients are usually kept under clinical post-treatment surveillance, including a combination of cytology, HPV-DNA testing and colposcopic examination. The objective of these monitoring activities is the early detection of patients at high-risk for residual/recurrent disease, with the aim of intensifying the diagnostic procedures or, conversely, returning to normal screening intervals.

Although many patient-related factors (age, smoking habits, number of sexual partners) and pathological characteristics (surgical margins, glandular involvement, lesion size, histological grade and antecedent cytological result) may affect the clinical outcome, the recurrence risk prediction is suboptimal. Women with clear margins following conservative treatment could be at risk for disease recurrence because a multifocal lesion may occur. Conversely, most women with positive resection margins (which suggest an incomplete excision of the lesion) do not develop recurrent disease over time, indicating a limited usefulness of this marker. Moreover, although usually conducted in the surveillance work-up, colposcopic examination has been shown to add little information to the detection rate of residual/recurrent HG-CIN [@B7], [@B8].Therefore an accurate test (or combination of tests) able to successfully predict clinical outlook, allowing reduction in the follow-up period and related negative issues (such as anxiety, psychosexual outcomes and overall health cost), would be particularly helpful.

Currently, despite the low-accuracy in detection of recurrent disease (corresponding to high sensitivity, but low specificity [@B9]), most women treated for high-grade CIN are still monitored by periodical cytological examination. Before returning to routine screening Luesley [@B10] proposed for CIN2+ patients a cytological follow-up at 6 and 12 months after therapy, and thereafter annually for the next nine years. Indeed, the pap-smear is probably still the most widely accepted follow-up procedure after conization, since the European guidelines for clinical management of abnormal cervical cytology [@B11] also recommend this test at 6, 12 and 24 months after cone biopsy.

However, a false-negative rate of pap-smears during follow up after treatment has been reported so far [@B1], [@B12], [@B13], [@B14]. Moreover, in the past decade it has emerged that HPV-DNA testing plays a relevant predictive role, over cytology, after ablative cervical excision. A positive post-treatment HPV-DNA test could predict HG-CIN recurrence more accurately than either cytology, or positive surgical margins, as described in the regression analysis by Paraskevaidis in 2001 [@B12] and in a subsequent systematic review [@B1]. To date, a wide range of literature from observational studies of prospective cohorts [@B7], [@B15], [@B13], [@B17], [@B19], [@B20], retrospective case-control study [@B21], [@B22], a large study conducted in an integrated health system [@B23] and meta-analyses or systematic reviews [@B1],[@B18], [@B24], [@B25],[@B27] attest to the usefulness of HPV-DNA test in clinical management after HG-CIN treatment.

It has been documented [@B28] that the vast majority of CIN3 patients are clear of HPV infection after 6 months from the excisional therapy, dramatically reducing the risk of actual/subsequent recurrence and thus being widely protected against cancer progression. Conversely, HPV infection persistence (and in particular of high-risk genotypes, hr-HPV) during the follow-up period is strictly related to residual or relapsed disease [@B1],[@B29]. This is because, as already stated [@B4], ablative treatment removes the dysplastic lesion but not necessarily all the infected tissue. Effective treatment thus results both from removal of the entire lesion and viral clearance as well. Therefore, hr-HPV-DNA persistence after therapy, which is a prerequisite of the original intraepithelial lesion and a critical key-point in cervical cancer oncogenesis [@B30], [@B69], may over time further promote the recurrence of disease [@B31],[@B32]. In other words, the persistent positivity of HPV-DNA testing in the follow-up surveillance after CIN2+treatment (detected in up to one-third of women [@B1], [@B12], [@B19] and even more [@B29]) assumes a true predictive role.

According to this background, surveillance strategies including a pooled hr-HPV-DNA testing (also defined as a *test-of-cure*) are reported to be more effective than conventional cytology alone, predicting treatment failure with significantly higher sensitivity and similar (or not-significantly lower) specificity compared to repeat cytology (Table [1](#T1){ref-type="table"}). Being a post-therapy monitor activity on high-risk women, not within a normal screening setting on general population, surveillance strategies should prefer sensitivity over the specificity rate, in order not to miss any recurrent disease. Indeed, a high sensitivity is repeatedly reported in the literature for HPV-DNA testing 6 months after conization, ranging from 90 to 100%, as well as a high negative predictive value, which is a relevant index to safely return to a normal screening schedule. Furthermore, hr-HPV-DNA test of cure would also be cost-saving compared with follow-up cytology, as reported by Legood et al [@B33] in a National Health Service Cervical Screening Programme setting.

Moreover, the combination of cytology [and]{.ul}pooled hr-HPV-DNA testing [@B7], [@B34] in a *"test-of-cure-setting"* [@B35] has been reported to offer greater sensitivity (over 93%) than cytology alone and excellent post-treatment negative predictive value (close to 99% or over), which is highly relevant in this post-treatment group of patients. Therefore, despite the fact that follow-up after CIN2+ conservative treatment has not yet been standardized (varying in terms of timing, interval, and methods), it should include cytology and hr-HPV-DNA testing at 6 months, for early detection of any patients at increased risk of recurrence and cancer progression. The negative result of the two combined tests may further omit the scheduled 12 months check-up examination, to move directly to 24 months after treatment, thus being a less costly procedure. In this regard, Kocken et al [@B4], [@B27] stated, through a meta-analysis, that the 5-year risk of post-treatment CIN2+ after three consecutive negative cytological smears or negative co-testing (cytology and hr-HPV testing) at 6 and 24 months was similar to that of women with normal cytology in population-based screening.

However, although the combination strategy promises to better monitor CIN2+ treated patients compared with using cytology alone, it still does not represent the standard follow-up so far. In fact, *Cochrane Review*by van der Heijden et al [@B36] found no useful randomized clinical studies directly comparing the two modalities of follow-up strategy (pooled hr-HPV-DNA testing with cytology vs conventional post-treatment cytological at 6-12 months), thus advocating the need for appropriate perspective studies.

HPV Genotyping
==============

To date, in this surveillance setting, few clinical studies have been conducted to evaluate whether HPV-genotyping will even more accurately predict outcome of HG-CIN-treated patients than will the pooled-probe hr-HPV test.

The objective of the type-specific HPV-test is to distinguish, after conservative therapy, the persistence of the same oncogenic papillomavirus involved in the cervical lesion. Indeed, by definition, to be classified as "*persistent*" the cervical infection should be ascertained as being related to the same genotype found within the original intraepithelial lesion. Since up to one-third of treated women are still HPV-positive at follow-up, the clinical question is whether this persistence is related to the same original genotype, or belongs to a new infection. In this regard caution must be applied into the evaluation of younger women who may have, after the treatment, a high rate of transient infection.

The literature on this matter, although based on few studies and a small number of patients, agrees to assign a prognostic role of type-specific HPV-testing, with a steady increase in sensitivity rate and a significantly higher specificity. Kreimer et al within the ALTS study [@B37], comparing three follow-up strategic methods, showed a better sensitivity for hr-HPV persistence with a better specificity compared with conventional follow-up. Analogous findings were reported by Heymans [@B21], where HPV genotyping showed both a significantly higher sensitivity and specificity to predict residual/recurrent CIN2+. Strand et al [@B38], recently reported that specific HPV genotype persistence predicts recurrent or residual disease more accurately than does simple pooled HPV-testing, improving the specificity (up to 100%) when using in post-treatment surveillance. Over three years of follow-up, no women with type-specific HPV-negative had recurrent disease and, vice versa, all of the recurrences were persistently positive with the same type. Similar data was also reported by Nobbenhuis [@B28], where 90% of recurrent CIN2+ were found to be infected by the same high-risk HPV type as before the initial treatment and, conversely, no recurrent disease has been reported in HPV-type specific negative cases. Similarly, outcomes have been reported by Kang et al [@B39] who stated that detection of the same hr-HPV genotype during follow-up was related to a sensitivity and negative predictive value of 100% for predicting residual/recurrent disease. Conversely, Brismar et al. [@B40] reported a reduction of sensitivity rate from 100% to 60%, as compared to oncogenic pooled test.

Similarly to sensitivity, specificity and positive predictive value are consistently described as increased due to HPV-genotyping [@B17],[@B21],[@B39],[@B40]. As expected, among HPV-positive women during the follow-up period, different genotypes confer different risks for post-therapy recurrence and, within the same genotype, variants may also provide additional risk stratification [@B41]. Patients still infected at 6 months from non-carcinogenic types had a very low-risk of recurrence over 2 years (1.5%), thus very close to HPV-negative women [@B17]. In this regard, after ablative therapy, a repopulation of cervical and/or vaginal epithelium has been described with low-risk HPV types (from previously infected vaginal walls, or from subsequent contamination), which therefore do not show any significant cancer risk.

Conversely, among high-risk genotypes, patients with HPV16 infection have a greater risk of developing CIN3+ [@B42], and hence its persistence during the follow-up time may be associated with higher recurrence risk and warrant separate detection. In recurrent patients HPV-16 tends to clear slowly and lesser than the other oncogenic types [@B22], confirming the clinical evidence of the ALTS trial [@B17] and other studies [@B22],[@B43],[@B21],[@B39], where persistent HPV-16 has been detected more frequently associated with recurrent disease. Women positive for HPV-16 at 6 months from cone biopsy [@B17] have higher risk (37%) of developing recurrent disease over 2 years, compared to those positive to HPV-18 (18.5%) or other carcinogenic genotypes (10.8%). Consistent with these data, Vintemyr et al. in a retrospective registry-based study in Norway [@B44], reported that 75% of recurrent CIN2+ cases were associated with types HPV 16/18. More recently, also Andrade et al. [@B22] confirmed a 3-fold greater risk of recurrence for HPV-16 persistence.

Although it has been recently reported [@B20] that a high percentage of HG-lesions related to HPV 16 or 18 may regress before treatment (thus suggesting that a pretreatment test would not have predictive information), hr-HPV genotyping promises to be useful into the clinical risk stratification. Women affected by HPV-16 high-grade disease need a more appropriate and intensive post-surgical follow-up, providing the opportune methodological test to identify its persistence over time. Conversely, although requiring more confirmation from the literature, a post-therapy detection of HPV genotype different from that present before cone-biopsy, may allow a reduction of the intensity of follow-up.

Finally, also viral load may be regarded as an HPV proxy measure of disease persistence. Many authors [@B7], [@B45], [@B46], [@B47] have reported that patients with low viral load were less likely to develop recurrent or persistent disease, while other do not confirm this [@B48], [@B49]. Although elevated hr-HPV loads have been associated with extensive lesions (more likely to recur), its predictive role is still debated. Indeed, many critical issues (regarding the value of single vs repeated load, pre- vs post-conization sample analysis, the impact of single vs multiple genotypes, the cut-off level expressed in RLU and the selected method for measurement as well) need to be further valued.

HPV Genotyping Methods
======================

Currently, several systems are available for HPV genotyping (Table [2](#T2){ref-type="table"}). However, they differ in their analytical performance, in terms of genotypes included, type-specific sensitivities and specificities. One of the main problems is the lack of standardization, and therefore the impossibility of comparing the results obtained by different laboratories. The results of an international proficiency study were recently published [@B50]: forty-three reference samples were prepared with complete genome of 17 HPV types (12 HR and 5 LR), cloned into plasmid vectors. Different amounts of plasmids were present in the samples and some contained multiple types. The more widely-used HPV genotyping systems were represented, as 96 laboratories participated, some of them providing data on different methods. The results of this survey indicate that, although there was an improvement over the results of the previous survey performed in 2008 [@B51], the systems still differ in their performance, and this could be due both to the test and to the overall performance of the laboratory.

Today two main groups of methods are commercially available. The first group is able to give a \'partial genotyping\', as these tests can detect, through dedicated channels, the presence of HPV-16 and of HPV-18 individually, while the other hr-HPV are detected in pool. These systems have undergone analytical and clinical validation [@B52], [@B53], [@B54], [@B55], [@B56], and some of them have also been cleared by the US FDA for the triage of ASCUS cytology and recently the Cobas4800 HPV Test (Roche Diagnostics, Pleasanton, USA) was cleared as a primary test in screening.

Like the Cobas 4800 HPV Test, the Abbott Real Time High Risk HPV test (Abbott Molecular, Des Plaines, IL, USA), belongs to the group of next-generation Real-Time-PCR based HPV DNA assays in which the detection of 14 HPV genotypes is combined with concurrent genotyping for HPV-16 and HPV-18: this test was launched on the European market in January 2009 and is currently used in many laboratories worldwide for routine detection of high risk HPV [@B57].

Another HPV test clinically validated for HPV genotyping is the Cervista HPV 16/18 test (Hologic, Inc., Madison, WI). This was the first HPV genotyping test approved by the FDA, and permits the differentiation only of HPV-16 and HPV-18 genotypes [@B58]. Among the different systems available, Qiagen HR-HPV 16/18/45 Probe Set Test is a signal amplification assay based on the most widespread hybrid capture technology (the first FDA validated method) using a probe mix comprising short sequence-specific synthetic probes designed for HPV-16, -18 and -45 detection.

Although these systems may provide sufficient information in more than 50% of patients, who are HPV-16 or HPV-18 positive with CIN2+ lesions, they are not suitable for the follow up of women bearing another hr-HPV. In these cases a second group of HPV genotyping methods, which provide an \'extended\' genotyping, should be used. Few systems have been validated for this purpose. They can give a specific response on the presence of single or multiple infections, and are based on different approaches. For example the Linear Array^TM^ HPV genotyping test (Roche Diagnostics) is a partially manual method, which is based on reverse line blot hybridization for the detection of 37 genotypes [@B59]. The same approach is also used for the INNOLIPA HPV Genotyping Extra (Innogenetics, Belgium), although the L1 region of the HPV genome used for amplification is much smaller compared to the Linear Array and the genotypes detected number twenty-eight [@B56]. Other methods are based on microarray technology. Examples include the Greiner Bio-One PapilloCheck assay (Greiner Bio-One GmbH, Germany), based on the amplification of a 350 bp fragment within the E1-region, which allows the simultaneous identification of 24 genotypes [@B60], [@B61], or the Clart® Papillomavirus Humano 2 (Genomica, Spain), which can detect 35 genotypes [@B62], or the fully automated Infiniti^TM^ Analyzer, based on the detection of different groups of HPV genotypes by using three different reagent kits [@B63].

Other systems will appear in the near future, and many are now under clinical validation. For example the BD Onclarity HPV assay(BD Diagnostics, Sparks, MD, USA): the Onclarity is a fully-automated E6-E7 DNA-based Real Time PCR assay that detects 16, 18, 31, 45, 51, 52 as single genotypes and the remaining eight genotypes in three groups (33/58, 56/59/66, 35/39/68)[@B64].

The large number of methods available means that it is important to be aware of the performance characteristics of the particular system in use, and to observe strict standardization of the process and observation of quality assurance criteria.

Conclusion
==========

Since HG-CIN recurrence after surgical therapy is a major marker for progression to invasive cancer, the strategy and procedures of follow-up represent a critical point for risk stratification. Monitoring activity with pooled hr-HPV-DNA testing during the surveillance period has been identified as an independent risk factor associated with recurrent disease, and thus may select those women at high-risk for recurrence [@B21], [@B17], reducing unnecessary and expensive procedures. The combination of pooled hr-HPV-DNA testing with cytology represents an accurate index of disease clearance and has been widely accepted (though not formally included into nationwide guidelines) in the routine post-treatment work-out of HG-CIN-treated patients. Furthermore, positive HPV-testing has been also identified, at any time during follow-up, as the most significant independent predictor of recurrent disease in the management of adenocarcinoma in situ [@B66]. Moreover, based on scientific knowledge and recent emerging data, type-specific HPV after HG-CIN therapy may be an even more significant marker (compared to pooled-based testing) for the development of disease recurrence. Detection at 6 months after conization of the same high-risk HPV genotype is reported to be a better predictor of recurrence in respect to pooled hr-HPV-DNA testing, with a comparable sensitivity and accompanied by a higher specificity. In particular, persistence of HPV 16/18 genotypes are reported to significantly impact on the recurrence rate after conization, thus requiring a close follow-up with immediate reference to colposcopy. Conversely, women negative for HPV type-specific persistence are considered at very low risk for recurrence, leading to a more individualized follow-up schedule. In Table [3](#T3){ref-type="table"}, a flow-chart for surveillance of HG-CIN, with an integration of HPV genotyping and cytology 6 months after conservative treatment, is suggested.

In conclusion, the excellent clinical performance of the combination strategy with HPV genotyping and cytology is considered a powerful tool for managing the post-treatment follow-up of high-grade cervical intraepithelial lesions. In addition, the choice of HPV-test remains of relevant importance given the increasing number of available assays on the market. All of the Authors of the present review use, in their own Institution, validated HPV-test (HC2, Cobas 4800 or Abbott Real Time) in a strategy as shown in Table [3](#T3){ref-type="table"} to follow CIN2+ treated patients. Although most of the commonly used assays were sensitive for detection of CIN2+ disease after therapy [@B67], [@B68], it is necessary to be aware of the performance of the system, observing strict standardization of the process and adhering to quality assurance criteria.
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###### 

Sensitivity and specificity rate of 6 months post-treatment HPV-DNA testing for detecting residual/recurrent CIN 2+

  --------------------------------------------------------------------
  Author                     Pts    \%\           \%\           \%\
                                    sensitivity   specificity   NPV
  ------------------- ------ ------ ------------- ------------- ------
  Paraskevaidis E     2001   123    93            84            \--

  Nobbenhius M        2001   184    93            86            99

  HoufflinDebarge V   2003   205    100           67            100

  Zielinski GD        2004   \*     91            79            98

  Sarian L            2004   107    80            82.9          

  Alonso I            2006   203    97.2          81.4          99.3

  Kreimer             2006   485    90.6          63.8          99.7

  Verguts J           2006   72     100           77.3          100

  Chan B              2009   \*\*   90.7          74.6          100

  Kang WD             2010   672    97.3          93.1          99.8

  Leguevaque P        2010   352    90.7          79.9          98.4

  Kocken              2011   435    92            76            \--

  Ryu                 2012   183    100           81.9          100
  --------------------------------------------------------------------

\* pooledmeta-analysis

\*\* systematic review

NPV: negative predictive value
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Available systems for HPV genotyping (the grey area is a pooled analysis of HPV genotypes)
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Flow-chart with integration of HPV-DNA test and pap-test 6 months after conservative treatment for CIN2+
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